This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/28/2023 11:56 AM

HOLD Page Industries

Not yet out of the woods; topline disappoints in Q2

Retail > Result Update > November 9, 2023

PAG's in-line Q2 result was a combination of a 5-9% revenue miss and a 160-180bps margin beat, on lower marketing spend, hiring freeze and an accounting change (Emkay: 40bps benefit). Volume decline persisted, with 9%/11% degrowth in Q2/H1, while the economy-segment players (*Lux/Rupa/Dollar*) saw 10-20% volume growth in H1, albeit lackluster revenue growth on pricing cuts. Headwinds—in the form of weak demand trends, inventory-laden peers (unusually high schemes to the trade) and senior-level (CRO/COO) exits—are unrelenting and may keep near-term growth in check. Even distribution expansion took a breather in H1FY24. While there is no change in our FY25/26 estimates, we upgrade our rating to HOLD (TP: Rs39,000/sh), as the stock has lagged benchmark indices by ~30% in the last 1 year. We adopt a conservative stance, as some company-specific issues may stretch the recovery.

Page Industries: Financial Snapshot (Standalone)										
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E					
Revenue	38,865	47,886	47,410	57,418	66,055					
EBITDA	7,855	8,627	9,234	11,408	13,573					
Adj. PAT	5,365	5,713	5,975	7,573	9,127					
Adj. EPS (Rs)	481.0	512.2	535.7	678.9	818.3					
EBITDA margin (%)	20.2	18.0	19.5	19.9	20.5					
EBITDA growth (%)	49.2	9.8	7.0	23.5	19.0					
Adj. EPS growth (%)	57.5	6.5	4.6	26.7	20.5					
RoE (%)	54.4	46.4	39.3	40.7	40.1					
RoIC (%)	93.8	53.7	43.4	47.6	47.5					
P/E (x)	78.3	73.6	70.4	55.5	46.1					
EV/EBITDA (x)	53.2	48.8	45.3	36.7	30.6					
P/B (x)	38.6	30.7	25.2	20.5	16.8					
FCFF yield (%)	0.6	(0.4)	2.1	1.0	1.9					

Source: Company, Emkay Research

Topline miss in Q2; hopes pinned on macro+channel inventory improvement: PAG saw revenue decline of ~8% in Q2, due to a 9% drop in volume. The revenue decline was owing to weak macros, channel rationalization and lower primary sales on account of a remnant ARS impact. Discounts/schemes remain high for peers, but PAG is not an active participant. Degrowth was seen across categories, with women's innerwear faring relatively better. Among channels, MBO/EBO saw decline in revenue, while E-commerce is seeing encouraging growth trends. Distribution expansion for MBOs was subdued, as PAG reduced its MBO distribution by 2,300 outlets sequentially. EBO expansion continued, with 40/83 additions in Q2/H1, taking the total count to 1,372. EBITDA margin was up by 180bps to ~21%, owing to lower marketing spend, hiring freeze, and change in accounting policy (Emkay: 40bps benefit). PAG expects margins to remain within the guided band of 19-21%, given focus on cost savings and inventory optimization.

Earnings-call KTAs: 1) The major share of ARS and channel rationalization is done, and the primary channel should largely reflect secondary sales going ahead; the EBO channel has always been under ARS. 2) Consumer trends should start improving with the onset of the festive season; but PAG has not yet seen a noticeable trend in the urban/premium segment. 3) PAG saw healthy growth of 31% in its e-commerce business in H1; overall, PAG has seen 9% de-growth in H1, indicating low traction in MBO/EBO channels. 4) PAG has not taken any price hike, and has no such intention in the near term either, given moderation in RM costs/other cost optimizations; benefit of the low-cost inventory should also gradually flow in. 5) With the industry logging high inventory in the premium segment, discounting pressure remains intense. PAG expects discounting to reduce, or it will lead to a sustainability issue in the long term for peers. 6) Efforts to improve the D2C channel continued, which grants confidence to PAG on improvement in customer acquisition. 7) Employee cost came in lower, with reasonable attrition in place and hiring freeze adopted, in view of the muted macro. 8) For CXO level exits, PAG is confident of a smooth transition through internal elevations. 9) PAG attributed the demand weakness to the rise in health cost and rentals as well as challenges in the IT services sector.



TARGET PRICE (Rs): 39,000

Target Price – 12M	Sep-24
Change in TP (%)	2.6
Current Reco.	HOLD
Previous Reco.	SELL
Upside/(Downside) (%)	3.5
CMP (09-Nov-23) (Rs)	37,686.6
Stock Data	Ticker
52-week High (Rs)	50,450
52-week Low (Rs)	34,953
Shares outstanding (mn)	11.2
Market-cap (Rs bn)	420
Market-cap (USD mn)	5,047
Net-debt, FY24E (Rs mn)	-2,394
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	1,029.0
ADTV-3M (USD mn)	12.4
Free float (%)	54.0
Nifty-50	19,395
INR/USD	83.3

Shareholding, Sep-23

45.1
22.0/23.6

Price Performance								
(%)	1M	3M	12M					
Absolute	(4.5)	(3.5)	(24.0)					
Rel. to Nifty	(3.9)	(2.3)	(28.8)					



Devanshu Bansal


devanshu.bansal@emkayglobal.com +91 22 6612 1385

Vishal Panjwani

vishal.panjawani@emkayglobal.com +91 22 6624 2431


Story in Charts

Exhibit 1: Comparable sales declined 8% in Q2 due to a subdued demand environment and channel rationalization




Source: Company, Emkay Research

Exhibit 3: MBO count declined by 1,900+ in H1, amid channel rationalization




Source: Company, Emkay Research

Exhibit 5: EBITDA margin improved to 21%, led by lower operating cost and a ${\sim}40\text{-}bps$ gain, on change in accounting




Source: Company, Emkay Research






Source: Company, Emkay Research

Exhibit 2: Volumes declined ~9%, while realization lowered by ~1% in Q2




Source: Company, Emkay Research

Exhibit 4: EBO additions were 43 in Q1, pushing up the total MBO-count to ${\sim}1.3k$




Source: Company, Emkay Research

Exhibit 6: Trade incentives inched up in Q2FY24 vs. historical trends



Source: Company, Emkay Research

Exhibit 8: Page's one-year forward P/E



Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/28/2023 11:56 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 9: Actual vs. Estimates (Q1FY24)

(Dama)	Actual		Estimates	Varia	ation	Commente
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	
Net Sales	11,251	11,893	12,317	-5.4%	-8.7%	Revenue was lower than our estimate led by weak demand
EBITDA*	2,335	2,275	2,324	2.6%	0.5%	Margin came in better than estimate, with lower marketing costs, hiring freeze and change in accounting policy
EBITDA margin*	20.8%	19.1%	18.9%	162	189	
PAT	1,503	1,467	1,514	2.5%	-0.8%	PAT was largely in line with expectations

Source: Company, Emkay Research; *Post IndAS-116 EBITDA

Exhibit 10: Summary of quarterly results

Y/E, Mar (Rs mn)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	FY23TD	FY24TD	Gr (%)
Operating Income	12,550	12,233	9,691	12,400	11,251	-10.3	-9.3	25,963	23,652	-8.9
Expenditure	10,172	10,305	8,348	9,982	8,916	-12.3	-10.7	20,606	18,898	-8.3
Consumption of RM	5,551	5,825	4,203	5,839	4,989	-10.1	-14.5	11,652	10,828	-7.1
as % of sales	44.2	47.6	43.4	47.1	44.3			44.9	45.8	
Employee Cost	2,301	2,148	2,203	2,087	2,038	-11.4	-2.4	4,461	4,125	-7.5
as % of sales	18.3	17.6	22.7	16.8	18.1			17.2	17.4	
Other expenditure	2,320	2,332	1,942	2,056	1,889	-18.6	-8.1	4,493	3,945	-12.2
as % of sales	18.5	19.1	20.0	16.6	16.8			17.3	16.7	
EBITDA	2,379	1,928	1,343	2,419	2,335	-1.8	-3.4	5,357	4,754	-11.2
Depreciation	188	200	213	210	246	30.9	17.3	368	457	23.9
EBIT	2,190	1,728	1,130	2,209	2,089	-4.6	-5.4	4,988	4,298	-13.8
Other Income	27	16	71	19	17	-37.6	-11.9	60	36	-40.3
Interest	92	100	136	127	112	22.0	-12.2	177	239	35.2
РВТ	2,125	1,645	1,065	2,100	1,994	-6.2	-5.1	4,871	4,094	-16.0
Total Tax	504	407	282	517	491	-2.6	-4.9	1,179	1,007	-14.6
APAT	1,621	1,237	784	1,584	1,503	-7.3	-5.1	3,692	3,086	-16.4
Minority Interest	0	0	0	0	0			0	0	
APAT (after minority)	1,621	1,237	784	1,584	1,503	-7.3	-5.1	3,692	3,086	-16.4
Extraordinary Items	0	0	0	0	0			0	0	
Reported PAT	1,621	1,237	784	1,584	1,503	-7.3	-5.1	3,692	3,086	-16.4
Adjusted EPS (Rs)	145.4	110.9	70.2	142.0	134.7	-7.3	-5.1	331.0	276.7	-16.4
(0)										<i>(</i> ,)
(%)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	(bps)	(bps)	FY23TD	FY24TD	(bps)
Gross margin	55.8	52.4	56.6	52.9	55.7	-10	270	55.1	54.2	-90
EBITDAM	19.0	15.8	13.9	19.5	20.8	180	130	20.6	20.1	-50
EBITM	17.5	14.1	11.7	17.8	18.6	110	80	19.2	18.2	-100
PBTM	16.9	13.4	11.0	16.9	17.7	80	80	18.8	17.3	-150
PATM	12.9	10.1	8.1	12.8	13.4	40	60	14.2	13.0	-120
Effective Tax rate	23.7	24.8	26.5	24.6	24.6	90	0	24.2	24.6	40

Source: Company, Emkay Research; *Post IndAS-116 EBITDA

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/28/2023 11:56 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 11: PAG vs peers

	Price	Мсар	_	Target	I	EPS (Rs)			P/E (x)		EV /	EBITDA	(x)*
Companies	(Rs/sh)	(Rs bn)	Reco	Price (Rs/sh)	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Titan Company	3,284	2,915	Hold	3,670	40.4	50.8	63.4	81.3	64.6	51.8	53.1	42.4	34.7
Page Industries	37,687	420	Hold	39,000	535.7	678.9	818.3	70.4	55.5	46.1	44.9	36.3	30.5
Jubilant FoodWorks	506	334	Sell	380	4.8	7.0	9.0	104.5	72.5	56.4	28.2	22.6	19.0
Devyani International	180	217	Sell	165	1.2	2.1	3.1	152.2	86.1	58.4	30.4	23.8	18.4
ABFRL	215	204	Hold	220	-5.1	-3.6	-2.2	-42.3	-59.2	-98.7	14.8	9.8	7.7
Westlife Development	811	126	Buy	1,040	6.6	10.1	15.1	123.4	80.3	53.7	30.3	23.8	18.7
Sapphire Foods	1,299	83	Buy	1,550	15.3	25.3	35.2	84.7	51.4	36.9	16.2	12.4	9.7
Varun Beverages	1,003	1,302	Buy	1,150	15.8	20.0	25.8	63.5	50.1	38.9	37.1	29.8	24.6
Go Fashion	1,228	66	Buy	1,440	17.2	24.5	32.5	71.4	50.2	37.8	26.0	19.5	15.1
Ethos	1,825	45	Buy	2,000	30.0	42.8	53.5	60.9	42.6	34.1	28.8	20.3	16.3
Senco Gold	702	55	Buy	800	21.6	27.6	35.0	32.4	25.4	20.1	16.7	13.3	10.8

Source: Company, Emkay Research; *Post IndAS-116 EBITDA

Exhibit 12: Changes in estimates

(Rs mn)		FY24E		FY25E			FY26E		
	Earlier	Revised	% Change	Earlier	Revised	% Change	Earlier	Revised	% Change
Revenue	47,410	47,410	-	57,418	57,418	-	66,055	66,055	-
EBITDA*	8,997	9,234	2.6	11,408	11,408	-	13,573	13,573	-
EBITDA margin (%)*	19.0	19.5	50 bps	19.9	19.9	0 bps	20.5	20.5	0 bps
Net profit	5,797	5,975	3.1	7,573	7,573	-	9,127	9,127	-
EPS (Rs)	519.8	535.7	3.1	678.9	678.9	-	818.3	818.3	-

Source: Company, Emkay Research; *Post IndAS-116 EBITDA

Page Industries: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	38,865	47,886	47,410	57,418	66,055
Revenue growth (%)	37.2	23.2	(1.0)	21.1	15.0
EBITDA	7,855	8,627	9,234	11,408	13,573
EBITDA growth (%)	49.2	9.8	7.0	23.5	19.0
Depreciation & Amortization	655	781	864	1,050	1,292
EBIT	7,200	7,847	8,370	10,358	12,281
EBIT growth (%)	55.3	9.0	6.7	23.8	18.6
Other operating income	0	0	0	0	0
Other income	210	147	125	175	201
Financial expense	322	413	528	476	361
РВТ	7,088	7,581	7,967	10,057	12,121
Extraordinary items	0	0	0	0	0
Taxes	1,722	1,869	1,992	2,484	2,994
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	5,365	5,713	5,975	7,573	9,127
PAT growth (%)	57.5	6.5	4.6	26.7	20.5
Adjusted PAT	5,365	5,713	5,975	7,573	9,127
Diluted EPS (Rs)	481.0	512.2	535.7	678.9	818.3
Diluted EPS growth (%)	57.5	6.5	4.6	26.7	20.5
DPS (Rs)	300.0	260.0	267.8	339.5	409.2
Dividend payout (%)	62.4	50.8	50.0	50.0	50.0
EBITDA margin (%)	20.2	18.0	19.5	19.9	20.5
EBIT margin (%)	18.5	16.4	17.7	18.0	18.6
Effective tax rate (%)	24.3	24.6	25.0	24.7	24.7
NOPLAT (pre-IndAS)	5,450	5,913	6,277	7,800	9,248
Shares outstanding (mn)	11.2	11.2	11.2	11.2	11.2

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	112	112	112	112	112
Reserves & Surplus	10,775	13,599	16,586	20,373	24,936
Net worth	10,886	13,710	16,698	20,484	25,048
Minority interests	0	0	0	0	0
Deferred tax liability (net)	0	0	0	0	0
Total debt	0	2,482	0	0	0
Total liabilities & equity	10,886	16,192	16,698	20,484	25,048
Net tangible fixed assets	3,094	3,375	4,833	7,638	8,737
Net intangible assets	20	26	26	26	26
Net ROU assets	(189)	(131)	(57)	24	113
Capital WIP	653	1,505	0	0	0
Goodwill	0	0	0	0	0
Investments [JV/Associates]	0	0	0	0	0
Cash & equivalents	2,835	81	2,394	2,006	4,549
Current assets (ex-cash)	13,558	20,491	18,834	22,023	24,431
Current Liab. & Prov.	9,084	9,154	9,332	11,233	12,808
NWC (ex-cash)	4,474	11,337	9,502	10,790	11,624
Total assets	10,886	16,192	16,698	20,484	25,048
Net debt	(2,835)	485	(2,394)	(2,006)	(4,549)
Capital employed	10,886	14,277	16,698	20,484	25,048
Invested capital	7,399	14,607	14,304	18,478	20,499
BVPS (Rs)	976.0	1,229.2	1,497.1	1,836.5	2,245.7
Net Debt/Equity (x)	(0.3)	0.0	(0.1)	(0.1)	(0.2)
Net Debt/EBITDA (x)	(0.4)	0.1	(0.3)	(0.2)	(0.3)
Interest coverage (x)	0.0	0.1	0.1	0.0	0.0
RoCE (%)	75.1	63.5	54.9	56.7	54.8

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	7,088	7,581	7,967	10,057	12,121
Others (non-cash items)	655	781	864	1,050	1,292
Taxes paid	(1,722)	(1,869)	(1,992)	(2,484)	(2,994)
Change in NWC	(2,846)	(6,863)	1,835	(1,288)	(833)
Operating cash flow	3,286	(104)	9,077	7,636	9,745
Capital expenditure	(952)	(1,545)	(495)	(3,500)	(2,000)
Acquisition of business	0	0	0	0	0
Interest & dividend income	210	147	125	175	201
Investing cash flow	(742)	(1,397)	(370)	(3,325)	(1,799)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	0	2,482	(2,482)	0	0
Payment of lease liabilities	(437)	(481)	(529)	(582)	(640)
Interest paid	(209)	(275)	(395)	(330)	(200)
Dividend paid (incl tax)	(3,346)	(2,900)	(2,988)	(3,786)	(4,564)
Others	(66)	(78)	0	0	0
Financing cash flow	(4,060)	(1,252)	(6,394)	(4,698)	(5,404)
Net chg in Cash	(1,515)	(2,754)	2,313	(387)	2,543
OCF	3,286	(104)	9,077	7,636	9,745
Adj. OCF (w/o NWC chg.)	6,132	6,759	7,242	8,924	10,579
FCFF	2,334	(1,649)	8,581	4,136	7,745
FCFE	2,222	(1,915)	8,178	3,835	7,585
OCF/EBITDA (%)	41.8	(1.2)	98.3	66.9	71.8
FCFE/PAT (%)	41.4	(33.5)	136.9	50.6	83.1
FCFF/NOPLAT (%)	42.8	(27.9)	136.7	53.0	83.8

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	78.3	73.6	70.4	55.5	46.1
P/CE(x)	69.8	64.7	61.5	48.8	40.3
P/B (x)	38.6	30.7	25.2	20.5	16.8
EV/Sales (x)	11.2	9.0	8.8	7.3	6.3
EV/EBITDA (x)	53.2	48.8	45.3	36.7	30.6
EV/EBIT(x)	58.0	53.6	49.9	40.4	33.9
EV/IC (x)	56.4	28.8	29.2	22.6	20.3
FCFF yield (%)	0.6	(0.4)	2.1	1.0	1.9
FCFE yield (%)	0.5	(0.5)	1.9	0.9	1.8
Dividend yield (%)	0.8	0.7	0.7	0.9	1.1
DuPont-RoE split					
Net profit margin (%)	13.8	11.9	12.6	13.2	13.8
Total asset turnover (x)	3.9	3.8	3.1	3.1	2.9
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	54.4	46.4	39.3	40.7	40.1
DuPont-RoIC					
NOPLAT margin (%)	14.0	12.3	13.2	13.6	14.0
IC turnover (x)	6.7	4.4	3.3	3.5	3.4
RoIC (%)	93.8	53.7	43.4	47.6	47.5
Operating metrics					
Core NWC days	(29.6)	(12.2)	(3.0)	(5.8)	(7.8)
Total NWC days	42.0	86.4	73.2	68.6	64.2
Fixed asset turnover	8.8	9.4	7.4	6.2	5.5
Opex-to-revenue (%)	35.8	36.7	34.7	34.7	34.2

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 11/28/2023 11:56 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
08-Oct-23	39,414	38,000	Sell	Devanshu Bansal
10-Aug-23	40,073	37,100	Sell	Devanshu Bansal
10-Jul-23	36,385	35,000	Sell	Devanshu Bansal
26-May-23	37,501	35,000	Sell	Devanshu Bansal
09-Apr-23	36,463	39,000	Hold	Devanshu Bansal
10-Feb-23	38,786	48,800	Buy	Devanshu Bansal
09-Jan-23	41,398	50,500	Buy	Devanshu Bansal
27-Dec-22	43,611	50,500	Buy	Devanshu Bansal
10-Nov-22	48,666	50,900	Hold	Devanshu Bansal
12-Aug-22	49,137	53,100	Hold	Devanshu Bansal
27-May-22	44,442	47,800	Buy	Devanshu Bansal

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/28/2023 11:56 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay@whitemarguesolutions com use and downloaded at 11/28/2023 11:56 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of November 9, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of November 9, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the November 9, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 11/28/2023 11:56 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.